Acetylsalicylic Acid In The Treatment And Prophylaxis Of Cardio-vascular Diseases: Issues Of Efficacy And Safety

P.S. Laguta

Acetylsalicylic acid in the treatment and prophylaxis of cardio-vascular diseases: issues of efficacy and safety
Antithrombotic therapy plays an important role in the treatment and prevention of many cardiovascular diseases. It has been proved that the antiplatelet agents administration result in decrease of overall vascular events risk by quarter, nonfatal myocardial infarction risk – by one third, nonfatal stroke - by quarter, vascular death – by one sixth. Aspirin (acetylsalicylic acid - ASA) remains the most accessible and widely used antithrombotic drug with clinical efficacy and safety proved by the results of numerous controlled trials and meta-analysis. It is well-established that low dose administration (75-150 mg daily) has the same efficacy as medium (160-325 mg daily) or high (500-1500 mg daily) dose administration. Multicenter study results analysis provides to recommend ASA in doses of 75-100 mg daily for chronic administration in patients with high risk of vascular complications. Loading ASA dose 160 mg is available in acute clinical conditions. Currently, ASA is widely used not only as monotherapy but in combination with other antithrombotics. ASA treatment is accompanied by a bleeding risk as well as any other antithrombotics treatment. However, ASC-induced gastropathy that aggravates ASA tolerability and reduces patients treatment compliance remains key problem. Under these circumstances, the important task is the use more safety ASC forms for ensuring long-term therapy.

Similar Articles

Бионика Медиа